呼出一氧化氮>300 ppb的患者发生呼吸衰竭及随后对度普利尤单抗的反应
Respiratory failure in a patient with exhaled nitric oxide >300 ppb and subsequent response to dupilumab.
作者信息
Crisp Howard
机构信息
North Texas Allergy and Asthma Associates and Division of Allergy/Immunology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA.
出版信息
Proc (Bayl Univ Med Cent). 2024 Aug 28;38(1):81-84. doi: 10.1080/08998280.2024.2395213. eCollection 2025.
Abstract
Multiple biologic agents are approved for the treatment of severe persistent asthma not controlled by inhaled corticosteroid/beta-agonist therapy. Appropriate phenotyping can aid in picking the right biologic for the right patient. Here is a unique case of a patient with severe asthma and respiratory arrest, with fraction of exhaled nitric oxide >300 ppb whose asthma became completely controlled with dupilumab.
摘要
多种生物制剂已被批准用于治疗经吸入性糖皮质激素/β受体激动剂治疗后仍无法控制的重度持续性哮喘。适当的表型分析有助于为合适的患者选择合适的生物制剂。以下是一个独特的病例，一名患有重度哮喘和呼吸骤停的患者，其呼出一氧化氮分数>300 ppb，使用度普利尤单抗后哮喘得到完全控制。
相似文献
1
Respiratory failure in a patient with exhaled nitric oxide >300 ppb and subsequent response to dupilumab.
Proc (Bayl Univ Med Cent). 2024 Aug 28;38(1):81-84. doi: 10.1080/08998280.2024.2395213. eCollection 2025.
2
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial.
Lancet Respir Med. 2025 Mar;13(3):208-220. doi: 10.1016/S2213-2600(24)00362-X. Epub 2025 Feb 10.
3
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
J Allergy Clin Immunol. 2024 Jul;154(1):101-110. doi: 10.1016/j.jaci.2023.09.044. Epub 2024 Jan 23.
4
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
5
Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma.
J Asthma. 2023 Jun;60(6):1162-1170. doi: 10.1080/02770903.2022.2136526. Epub 2022 Nov 15.
6
Prediction of Clinical Response to Dupilumab in Patients with Severe Asthma Using Fractional Exhaled Nitric Oxide Combined with Pulmonary Function Testing.
Int Arch Allergy Immunol. 2024;185(9):856-864. doi: 10.1159/000538542. Epub 2024 Apr 30.
7
[Mexican consensus on fractional exhaled nitric oxide (FeNO) in asthma 2020].
Rev Alerg Mex. 2020;67 Suppl 2:S1-S25. doi: 10.29262/ram.v67i0.760.
8
Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study.
Respiration. 2024;103(1):10-21. doi: 10.1159/000535390. Epub 2023 Dec 12.
9
Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial.
Chest. 2012 Dec;142(6):1553-1561. doi: 10.1378/chest.12-1310.
10
Relationship between fraction of exhaled nitric oxide and peripheral eosinophilia in asthma.
Ann Med. 2024 Dec;56(1):2382377. doi: 10.1080/07853890.2024.2382377. Epub 2024 Jul 25.
本文引用的文献
1
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.
J Allergy Clin Immunol Pract. 2023 Apr;11(4):1213-1220.e2. doi: 10.1016/j.jaip.2022.11.043. Epub 2022 Dec 16.
2
FeNO in Asthma.
Semin Respir Crit Care Med. 2022 Oct;43(5):635-645. doi: 10.1055/s-0042-1743290. Epub 2022 Mar 4.
3
Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion.
J Allergy Clin Immunol Pract. 2022 Feb;10(2):422-432. doi: 10.1016/j.jaip.2021.10.059. Epub 2021 Nov 8.
4
Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial.
J Asthma Allergy. 2021 Aug 16;14:1045-1063. doi: 10.2147/JAA.S318892. eCollection 2021.
5
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma.
Eur Respir J. 2021 Oct 7;58(4). doi: 10.1183/13993003.04605-2020. Print 2021 Oct.
6
High fractional exhaled nitric oxide levels in asthma patients: Does size matter?
Pediatr Pulmonol. 2021 Jun;56(6):1449-1454. doi: 10.1002/ppul.25333. Epub 2021 Mar 17.
7
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation.
Eur Respir J. 2021 Aug 5;58(2). doi: 10.1183/13993003.03393-2020. Print 2021 Aug.
8
Allergen immunotherapy and biologics in respiratory allergy: friends or foes?
Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):16-23. doi: 10.1097/ACI.0000000000000707.
9
The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma.
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1267-1275. doi: 10.1016/j.jaip.2020.09.051. Epub 2020 Oct 8.
10
The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment.
J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):640-648. doi: 10.1016/j.jaip.2016.11.024. Epub 2016 Dec 30.
Zotero 插件